CA2079703C - Novel 9-amino-7-substituted-6-demethyl-6-deoxytetracyclines - Google Patents

Abstract

Novel 9-amino-7-(substituted amino)-6-de-methyl-6-deoxytetracyclines having activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines are disclosed. Also disclosed are intermediates and methods for making the novel compounds of the present invention.

Description

31,681 Title: NOVEL 9-AriINO-7-(SUBSTITUTED)-6-1. Field of the Invention The invention relates to novel [4S-(4a,12aa))-9-amino-4-(dimethylamino)-7-(substituted amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides, hereinafter called 9-amino-7-(substituted amino)-6-de-methyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibacterial agents.
The invention also relates to novel 7-(substituted amino)-9-nitro-6-demethyl-6-deoxytetracycline compounds useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.
DESCRIPTION OF THE PRIOR ART
A variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947.
Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experi-mental Pharmacology, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major mechanisms of bacterial resistance to 2fl'~!~~fl3 tetracyclines: a) energy-dependent efflux of the anti-biotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B. Levy, et al., Antimicrob. Agents Chemotherapy 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which in-teracts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A.
l0 Salyers, B. S. Speers and N. B. Shoemaker, Mol.
Microbiol, 4:151-156, 1990). The efflux mechanism of resistance is encoded by resistance determinants de-signated tetA-tetL. They are common in many Gram-nega-tive bacteria (resistance genes Class A-E), such as Enterobacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram-positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N and O, and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and M~coplasma (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156 1990).
A particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. 3,148,212, RE 26,253 and 3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK (efflux in Staphylococcus) are resistant to minocycline. Also, strains carrying tetM (ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and mino-~~~~~~a cycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance determinants.
Duggar, U.S. Patents No. 2,482,055, discloses the preparation of Aureomycin~ (I) by fermentation which have antibacterial activity. Growich et al., U.S. Patent No. 3,007,965, disclose improvements to the fermentation preparation of :C. Neither of these patents teaches or suggests the 6-demethyl-6-deoxy-l0 tetracyclines.
C1 ~H30H NCCH3>z OH
I. ~ M.°, M.,; I
~ NH2 OH

Beereboom et al., U.S. Patent No. 3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH3: R1 is H and when R is CH3, OH; R2 is H and N(CH3)2; X and Y are halogen; Z is H and halo-gen and B is bromo, chloro and iodo, which have anti-bacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at Y or Z) and an amino function (at B).

OH OH
3 0 ~' ~\ H~~~ H~~ ~ ~ M M°
' / NHZ ~ / NH2 X OH X OH

Boothe et al., U. S. Patent No. 3,148,212, reissued as RE26,253, and Petisi et al., U.S. Patent No. 3,226,436, discloses tetracycline derivatives of the formula (IV) -4- 2~'~~"~~:3 wherein R is hydrogen or mei:hyl and R1 and R2 is hydro-gen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R1 and R2 cannot both be hydro-gen, which are useful for treating bacterial infec-tions. This patent does noi: teach or suggest the in-clusion of a 9-amino functionality (at R2).
R~ R N(CN3)=
OH
~\
H\'v: '',, \ ~ NHZ
RZ ~ ~0~~

IY
Blackwood et al., U.S. Patent No. 3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydro-gen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X1 may be hydrogen, amino, and lower alkanoyl-amino, X2 may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitro-gen functionality (at X1) on the 6-demethyl-6-deoxy-tetracycline nucleus.
X CH2 Y N<CH~)2 X CHp Y N<CH~>z OH ~ OH
X ~ / ~, ~ \,,- ~ NH2 I' / ~': M''1: H~NH
1 H ~ ~H OH~ ~ x ~ ~~~OH o 00 r vi Petisi et al., U.S. Patent No. 3,338,963 discloses tetracycline compounds of the formula (VII) wherein R1 and R2 are hydrogen, nitro, amino, formylamino, acetyl-amino, p-(dihydroxyboryl)benzoylamino, _5__ 2p'~~'~~3 p-(aminobenzenesulfonyl)amino, chlorine, bromine or diazonium with the proviso that R1 and R2 may not both be hydrogen and with the further proviso that when R1 is chlorine or bromine, R2 may not be hydrogen and vice versa, R3 is hydrogen or methyl and R4 is hydrogen or hydroxy, which have broad-spectrum antibacterial activ-ity. This patent does not teach or suggest the inclu-sion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R1) and amino substituents (at R2).
R1 R3 R4 NCCH3)2 OH
M',; Mo,,.
R ' / \ I NH2 pH ~ ~BH~~
vll Bitha et al., U.S. Patent No. 3,341,585 discloses tetracycline compounds of the formula (VIII) wherein R5 is hydrogen, a-hydroxy or ~-hydroxy, R6 is a-methyl or ~-methyl, and R~ and R9 are each hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R~ and R9 cannot both be hydrogen and with the further proviso that when R5 is hydrogen then R6 is a-methyl. A preferred embodiment of the general for-mula (VIII) is when R5 is a-hydroxy or ~-hydroxy, R6 is a-methyl or ~-methyl, R~ is di(lower alkyl)amino and R9 is hydrogen, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R~) and amino substituents (at R9).

R~ R6 R5 NCCH3)2 OH
R ' ~ \ I NH2 OH ~ off OH O
VIII
Shu, U.S. Patent No. 3,360,557 discloses 9-hydroxy-tetracyclines of the formula (IX) wherein R1 is hydro-gen or hydroxy, R2 is hydrogen or hydroxy, R3 is hydro-gen or methyl, R2 and R3 taken together is methylene, and R4 is hydrogen, halogen, vitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity. This patent is restricted to ~-hydroxytetracyclines and does not teach or suggest the presently claimed compounds.
R4 R3 R2 R1 N<CH3)2 ~\ OH
I. M.,,,. H'.,;
\ I NH2 H 0 ~ ~0~

IX
Zambrano, U.S. Patent No. 3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R5 is hydrogen or hydroxy, R1 is hydrogen or hydroxy, R6 is hydrogen or methyl, R1 and R6 taken to-gether is methylene, R7 is hydrogen, chloro or vitro and Rg is hydrogen or vitro with the proviso that R7 and R9 cannot both be hydrogen. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at 35' R7) and an amino functionality (at R9).

~~'~Q~03 _7_ R7 R6 R1 R5 N<CH3>2 , OH
~\
\ NH2 CI H

X
Martell et al., U.S. Patent No. 3,518,306 discloses 7-and/or 9-(N-nitrosoalkylamino)-6-demethyl-6-deoxy-tetracyclines of the formula (XI) which possess in vivo antibacterial activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at C-7) and an amino functionality (at C-9).
NCCH3)z N0(R)N - ' NHz XI
In U.S. 5,021,407, a method of overcoming the resistance of tetracycline resistant bacteria is dis-closed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms.
In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetra-cyclines.

_g_ SUMMf~RY OF THE INVENTION
This inventic:.-i is concerned with novel 9-amino--7-(substituted aminoj -6-d~~rnethyl-6-deoxytet_.racycli.nes, represented by formula s: <~nd II, which have antibacterial activity, with methods ~ai~ treating infectious diseases in warm-blooded animals emp:Loy.i.ng these new compounds; with methods of tre~rting or contro:Lling veterinary% diseases; with pharmaceutical preparations containing these compounds; with the use of there compounds and compositions thereof for treating, preventing ox controlling bacterial infections in warm-blooded animals; ~lil~h the use of= these compounds and compositions thereof fc~r preparing a medicament for treating, preventing o:e controlling bacterial infections in warm-blooded animals; ~rith commercial packages comprising these compound: or com~vo,~itions thereof and :Lnstructions associated therewith fc~r use of the compounds or compositions for treating, preventing or cantrolling bacterial infe~Jtions it warm-blooded animals; with novel intermediate c«mpounds and processes for the production of these compound's. More particularly, this invention is concerned witru compoun<:~.s of formula I which have enhanced in vitro and in vivo antiL:~acterial activity against tetracycline w°sista:nt strains as we:l1 as a :hi.gh level of activity against straim~> which are normally susceptible to tetracyclines.

~Q"~~'~~3 N(CH3)2 OH
i ~ s \ Hv.; Hw.,,.
' ~ \ NH2 Formula 1 H(CH3)2 OH
H~~~~,. H~°~, I / R 3 \ = NHCH2H~
HZH OH
OH 0 'OH 0 0 Formula II
In formula I and II, R=NR1R2, and when R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl:
and when R1=n-propyl, R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl, R2=2-methylpropyl;
R3 is selected from hydrogen, straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, ~~'~~'~~3 -lo-a-naphthyl or p-naphthyl: (C,~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R5 is selected from hydro-gen: straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl: or (C6-C10) l0 aryl group such as phenyl, a-naphthyl, p-naphthyl;
R4 is selected from hydrogen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or ~-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3--thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nC00R6 when n=1-4 and R6 is selected from hydro-gen; straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl: or (C6-C10)aryl such as phenyl, a-naphthyl or ,B-naphthyl; or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal com-plexes.
Particularly preferred are compounds accord-ing to the above~formula I and II in which R=NR1R2, and when R1=hydrogen, R2=ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, 2-methylpropyl or 1,1-dimethylethyl:
and when R1=methyl, R2=methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl:
and when R1=ethyl, 209'703 R2=ethyl, n-propyl, n-butyl or 2-methylpropyl;
and when R1=n-propyl, R2=n-propyl, n-butyl or 2-met:hylpropyl;
and when R1=n-butyl, R2=n-butyl or 2-methylpropyl;
R3 is selected from hydrogen, straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3--thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R5 is selected from hydro-gen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10) aryl group such as phenyl, a-naphthyl, p-naphthyl;
R4 is selected from hydrogen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or ~9-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOOR6 when n=1-4 and R6 is selected from hydro-gen; straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl such as phenyl, a-naphthyl or ~9-naphthyl; or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pYrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal com-plexes.

_12_ 2~~~"l~3 Most particularly preferred are compounds according to the above formula I and II in which R=NR1R2, and when Rl=hydrogen, R2=ethyl, n-propyl or 1-methylethyl;
and when Rl=methyl, R2=methyl, ethyl or n-propyl: and when R1=ethyl, R2=ethyl;
R3 is selected from hydrogen, straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl: (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(Cl-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R5 is selected from hydro-gen: straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10) aryl group such as phenyl, a-naphthyl, p-naphthyl;
R4 is selected from hydrogen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or ~-naphthyl; (Cy-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pYridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R6 is selected from hydro-gen; straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl such as phenyl, a-naphthyl or p-naphthyl: or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(Cl-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from 2~°~~'~~3 -1~-(L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal com-plexes.
Also included in the present invention are compounds useful as intermediates for producing the above compounds of formula I. Such intermediate com-pounds include those having the formulae:
to R N(CH3)2 OH
H,,,,,. H~,.,,. I

Formula III
R H(CH3)2 OH
H~ H~ I R

NHCHZN~
OZH pH R~
OH 0 OH 0 p Formula IV
wherein:
R=NR1R2' and when R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-propyl, R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl, ~0°~~'~fl3 R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when Rl=n-butyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl, R2=2-methylpropyl;
R3 is selected from hydrogen, straight or branched (Cl-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl: (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl: (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R5 is selected from hydro-gen;. straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-Cl0) aryl group such as phenyl, a-naphthyl, ,B-naphthyl;
R4 is selected from hydrogen: straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl: (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl: (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(Cl-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOOR6 when n=1-4 and R6 is selected from hydro-gen: straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl such as phenyl, a-naphthyl or ~9-naphthyl: or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pYrrolidine or piperidine: and the pharmacologically acceptable organic and inorganic salts, and metal com-plexes.

Particularly preferred are compounds accord-ing to the above formula III and IV in which R=NR1R2, and when R1=hydrogen, R2=ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl, R2=methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=ethyl, R2=ethyl, n-propyl, n-butyl or 2-methylpropyl;
and when R1=n-propyl, R2=n-propyl, n-butyl or 2-methylpropyl;
and when R1=n-butyl, R2=n-butyl or 2-methylpropyl;
R3 is selected from hydrogen, straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or ~9-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nC00R5 when n=1-4 and R5 is selected from hydro-gen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10) aryl group such as phenyl, a-naphthyl, ~-naphthyl;
R4 is selected from hydrogen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 3~ 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or' 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pYridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nC00R6 when n=1-4 and R6 is selected from hydro-gen: straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl such -16- 20'9703 as phenyl, a-naphthyl or p-naphthyl; or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts, and metal com-plexes.
Most particularly preferred are compounds according to the above formula III and IV in which R=NR1,R2, and when R1=hydrogen, R2=ethyl, n-propyl or 1-methylethyl;
and when R1=methyl, R2=methyl, ethyl or n-propyl;
and when R1=ethyl, R2=ethyl;
R3 is selected from hydrogen, straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or p-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOORS when n=1-4 and R5 is selected from hydro-gen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10) aryl group such as phenyl, a-naphthyl, p-naphthyl;
R4 is selected from hydrogen; straight or branched (C1-C3)alkyl group such as methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group such as phenyl, a-naphthyl or ~-naphthyl; (C~-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group such as 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOOR6 when n=1-4 and R6 is selected from hydrogen; straight or branched (C1-C3)alkyl such as methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl such as phenyl, a-naphthyl or ~-naphthyl;
or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)-alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from . (L or D) proline, ethyl (L or D) prolinate, morpholine, l0 pYrrolidine or piperidine; and the pharmacological2_y acceptable organic and inorganic salts, and metal com-plexes.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The novel compounds of the present invention may be readily prepared in accordance with the follow ing schemes.
The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1, wherein R=NR1R2 and R1=R2 (la) and R=NHR2 (1b) or the salts thereof are prepared by procedures known to those skilled in the art including those described in U.S.
Patents 3,226,436 and 3,518,306.
R N(CH3)2 OH
I \
H\''',' H\'',,' \ NH2 - OH

3~
to - R-NR~R2, R~-RZ
Ib - R-NHRZ
is - R-NR~RZ, R~~ R2 20'~9"~03 The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1 wherein R=NR1R2 and R1 ~ R2 ~1c) are prepared according to Scheme 1.

_1g_ Seh~m~ 1 Rt R:
NHR2 NCCH3)z N NCCH3)z OH DH
I '~ "~ I I H' M° I
/ \ NH2 / \ NHz OH ~H

R~~R=
25 In accordance with Scheme I, a 7-(monoalkylamino)-6-de-methyl-6-deoxytetracycline, 1b, in which R=NHR2, is reductively alkylated with an aldehyde to give an unsymmetrical dialkylamino, lc.

Sohamo 11 R N(CH3)z R N(CH3)z OH -,~ ,~ OH
M.~,. Mv~. I ~ H'r,. M~,, ~ / \ NHZ / \ I NHz H 0 H aH D 0 ~ OH OH
1 a,b, or o 1 R N(CH3)2 OH
I \ EN",. Mw.
\ . I NH2 HzN ~ ~ OH~
~H 0 OH 0 0 -In accordance with Scheme II, a 7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 1a-1c, is treated with a) a metal nitrate salt; such as calcium, potassium or sodium; and a strong acid; such as sulfuric acid, tri-. fluoroacetic acid, methanesulfonic acid or perchloric acid or b) nitric acid and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid; to form the corresponding 7-(substi-tuted amino)-9-nitro-6-demethyl-6-deoxytetracycline 2.

~~~~~~~) To produce the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines of the present invention, compound 2 or its salts is treated with hydrogen in an acid alcohol solvent, preferably 2-methoxyethanol, in the presence of a suitable catalyst such as, for example:
a) any supported catalyst; such as 0.5-25% palladium-on-carbon, 0.5-25% palladium-on-barium sulfate, 0.5-25%
platinum-on-carbon or 0.5-25% rhodium-on-carbon;
b) any reducible metal oxide catalyst; such as Raney nickel or platinum oxide; or c) a homogeneous hydrogenation catalyst; such as tris-(triphenylphosphine)rhodium (I) chloride; to obtain the 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetra-cycline, 3.
Alternatively, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines of the present invention are obtained by treating with:
a) stannous chloride dihydrate as described by R. B.
Wordward, Org. Syn., Coll. Vol. 3, 453 (1955);
b) a soluble metal sulfide, preferably sodium sulfide, in alcoholic solvents as described by G. R. Robertson, Org. Syn., Coll. Vol. 1, 52 (1941);
c) an active metal in mineral acid; such as iron, tin or zinc in dilute hydrochloric acid;
d) active metal couples; such as copper-zinc, tin-mer-cury or aluminum amalgam in dilute acid; or e) transfer hydrogenation using triethylammonium for-mate and a supported catalyst as described by I. D.
Entwistle et al., J. Chem. Soc., Perkin 1, 443 (1977).

2 Q'~ ~'~ Q 3 -22.-SvA~mv III
R N(CH3)z R N<CH3)Z
OH OH
v.
I NH~ I / ~ \ . ~ NHCHZIt~Rf OH Z aH ~s a s - -In accordance with Scheme III, Z=N02 or NH2 compound 4 is selectively N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D) lysine, (L or D) alanine or their substituted congeners; or a secondary amine such as morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adducts, 5, of the biologically active 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines. Contemplated equivalents include those substituted morpholine, pyrrolidine or piperidine moieties wherein the substituents are chosen to provide the requisite increase in solubility without adversely affecting antibacterial activity.
The 9-amino-7-(substituted amino)-6-de-methyl-6-deoxytetracyclines, 3, may also be obtained as metal complexes such as aluminum, calcium, iron, magne-sium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art. Pre-ferably, the 9-amino-7-(substituted amino)-6-de-methyl-6-deoxytetracyclines, are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate, alkylsulfonate or arylsulfonate. In all cases, the salt formation occurs with the C(4)-di-methylamino group. The salts are preferred for oral and parenteral administration.

2 ~t .
Biolocrical Activity Methods for In Vitro Antibacterial Evaluation (Table 1) The minimum inhibitory concentration (MIC), the lowest concentration of t:he antibiotic which inhi-bits growth of the test organism, is determined by the microtiter broth dilution method using 0.1 ml Muller-Hinton II broth (Baltimore Biological Laborato-ries) per well. A suitable oxygen scavenger (i.e., cysteine or dithiothreitol) is added to the assay medium for the testing of compounds according to For-mula I because of the sensitivity of those compounds to oxidation. An inoculum level of 1-5 x 105 CFU/ml and a range of antibiotic concentrations (32 -0.004 ~g/ml) are used. MIC's were determined after the plates were incubated for 18 hours at 35°C in a forced air incuba-tor.
E. coli in vitro protein translation system (Table 2) The E. coli in vitro translation system can be used to study not only the mechanism of protein translation itself, but also the effect that various compounds may have on protein synthesis. The system can be set up to function as a coupled transcription and translation system or as a translation only system depending on whether DNA or RNA is added to initiate protein synthesis. In this way, compounds affecting either RNA synthesis and/or protein synthesis can be studied. Protein synthesis is monitored by the incor-poration of radiolabeled amino acids into trichloro-acetic acid precipitable material. The system used is based upon literature methods (G. Zubay, Ann. Rev.
Genet., 7: 267-287(1973) and J. Collins, Gene, 6: 28-42 (1979)).
The system used to study tetracycline protein synthesis inhibition is as follows:
An S30 extract (supernatant from a 30,000 x G
centrifugation of lysed cells) of either tetracycline sensitive or tetracycline resistant (tetM+) cells is combined with a mixture of low molecular weight com-pour~ds required for protein synthesis which include a mixture of 19 amino acids, methionine, 35S-methionine, plasmid template DNA and either dimethylsulfoxide (DMSO) or the tetracycline to be tested dissolved and diluted in DMSO. This mixture is incubated at 37°C for 30 minutes. Following the incubation, 2.5 ~l of the l0 10 u1 reaction is removed and added to 0.5 ml of 1N
sodium hydroxide. The solution is incubated an addi-tional 15 minutes at 37°C, to destroy any m-RNA and t-RNA. The incorporation of 35S-methionine is deter-mined by precipitating the high molecular weight mate-rial in the sodium hydroxide aliquot with trichloro-acetic acid (TCA), collecting the precipitated material on Whatman G/FC filters, drying the filters and count-ing the radioactivity retained on the filter. Percent inhibition (P.I.) of protein synthesis is determined by the following equation:
total CPM* retained on filter in the P.I.=100 presence of added tetracycline compound X100 Total CPM* retained on filter for DMSO (control) *CPM = counts per minute In Vivo Antibacterial Evaluation (Table 3) The therapeutic effects of tetracyclines are determined against acute lethal infections with various staphylococcal and E. coli strains. Female mice, strain CD-1 Charles River Laboratories, (20 + 2 grams) are challenged by an intraperitoneal injection of suf ficient bacteria (suspended in broth or hog gastric mucin) to kill non-treated controls within 24-48 hours.
Antibacterial agents, contained in 0.5 ml of 0.2% aque-ous agar, are administered subcutaneously or orally 30 minutes after infection. When an oral dosing schedule is used, animals are deprived of food for 5 hours be-fore and 2 hours after infection. Five mice are treat-ed at each dose level. The 7 day survival ratios from 26 ~~"~~"~~J
three separate tests are pooled for calculation of me-dian effective dose (ED50)' I

Leaend for Tables I - III
A = 9-Amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride B = 7-(Dimethylamino)-6-demethyl-6-deoxytetra-cycline hydrochloride (minocycline hydrochloride) C = 9-wino-7-(diethylamino)-6-demethyl-6-deoxytetra-cycline sulfate D = 7-(Diethylamino)-6-demethyl-6-deoxytetracycline sulfate 'table 1 ~~~~~° C
In Vitro Antibacterial Activity of 6-Demethyl-6-deoxytetracycline Derivatives Organism' Via- ~ ~n_ -1?

S. aureus UBMS 88-5 (tetM) 0.06 4 U.5 16 S. aureus UBMS 88-4 (tetracycline-sensitive)0.015 0.008 O.U3 U.03 S. aureus DBMS 90-1 (tetM) 0.25 4 2 8 S. aureus UBMS 90-2 (tetM) 0.06 1 U.25 8 S. aureus UBMS 90-3 (tetracycline-sensitive)0.015 0.015 0.03 U.U3 S. aureus DBMS 88-7 (tetl~ 0.12 0.03 O.U6 U.12 S. aureus IVES 2943 (methicillin-resistant)0.5 1 0.25 8 S. aureus IVES 1983 (methicillin-resistant)0.5 1 0.25 8 S. aureus CI 2371 (methicillin-resistant)0.5 4 NA NA

S. aureus CI3300 (methicillin-resistant)U.25 8 NA NA

Coagulase negative staphylococci0.003 0.015 NA NA

Coagulase negative staphylococci1 8 NA NA

S. haemolyticus AVAH 88-3 0.06 0.12 0.12 NA

E. faecalis AMV 120 (tetM) 4 16 NA NA

E. faecalis PAM 211 (tetl~ 4 16 NA NA

E. faecalis 12201 (vancomycin-resistant)U.5 4 NA NA

E. faecalis CI 2735 0.5 4 NA NA

E. coli UBMS 88-1 (tetB) >32 8 2 32 E. coli UBMS 88-2 (tetracycline-sensitive)0.25 0.5 0.5 2 E. coli UBMS 89-1 (tetM) 1 8 2 NA

E. coli UBMS 89-2 (tetracycline-sensitive)U.5 0.5 U.5 =1 E. coli UBMS 90-4 (tetM) 4 >32 32 >32 E. coli UBMS 90-5 (tetracycline-sensitive)0.25 0.5 1 2 M. morganii NEMC 87-119 2 2 2 32 S. marcescens FPOR 87-33 4 2 4 32 P. aeruginosa ATCC 27853 2 4 8 32 X. maltophilia FPOR 87-210 0.12 0.06 0.12 U.25 E. coli ATCC25922 0.25 0.25 O.SU 1 E. faecalis ATCC 29212 0.06 0.25 0.12 H

S. aureur ATCC 29213 0.008 SO.OU4 <_0.015 <U.0 15 a In vitro assay is done tibacterial as not in the presence of cysteine potency enhanced (0.05%). An of B ii and D
w the presence of cysteine.

* The tetM resistance determinant protects ribosomes from tetracycline, the tetK determin:utt pI0I11otC5 ClIZuX

of the drug from the cell.

* .

~D M U V1 N O~~O ~O
M ~D p -,ooo o.o.ooo'~t~c~~n ~~o ~ vM.

x ~

.. .

N ~ M ~
M ~
r .-. M N O ~t ~p ' N O O
i O ~

~ p ~ N o0 M ..N O V1 t~
-r U Ov ,_ .., p M

00 N I~ ~r1 00 ~D
~ ~ O ~f ~~1 M N_ I~-~ ~-~ N N ~ ~ N N
n M M dy x , ooNOvN~IVI~D ~~~~000 p o0 00 n I~
~1 M ~t G

O

V1 Vii' V'1 ,.

~ ~ p N M
w N (~ ~i' ~
nr ~
O ~ I~ V'1 O ,~ N ~ v~ t~ Ov o0 M
ONN ~ Y1 ~~~~ O
NhOMOV

V ~ N N ~ -n N N
M M M

~i O

O y * .

M .~ ~ M ~ ~O I~
,...,r- ~D I~ ~. A ' ~ O O O
o.o~oooo~~ov .~N...

~
x b .,...3 _.

H ~

'' ~ ~ ~ Ov ~ t~ ~1 Ov o0 G o~0 ~ M U M I~
I~ M ~O
M I~ 00 M

O 00 Ov ~ ~ N 00 V' M ~

N
00 00 _ ~ n ~ .~ M ~
~ Ov o0 M
~

~ ~ ~ ~"'~ ~ M M C
O O N ~!1 ~1 ~f' V
~ ~

~

_ C

x CJ o~ooMOO~o~~MO ' 0000000 a G
A x r. G o N
CCf V1 n O ~--~ 00 00 M V1 M 00 OWE) NM pvpvNV

N
~ ~ ~ ~ ~ V1 <T
M N

1~ N M_ I~ 1~ 00 00 OW
'n ~ N U
~
~

~~ N NNNNNNN
NMV

~ ~

~~~ ~~~ s 0 0 o ~ ~ ~ ~ 0 D

La -a _ ~ .~~~-~' - ~
-n y-n-n a ~
~

~
~~~~

O O N ~t o0 p O N '~ 00 ~ .-r M ~ ~ .-. M
' U -; .-. ~ .. ... .-, ~ '-: .=: ~ U . . . .
.--. . 0. .- .=.:
.-. .~

_ . 20'~9'~~~

Table 3 Effects of Compounds A and B on Acute Lethal Infections in Mice ED~ r, ~mg/~+

Organism Route of AntibioticA B

Administration's E. coli 311 (sens) Subcutaneous 2.8 3.1 E. colt UBMS 90-4 (tetM) Subcutaneous 24 >256 S. aureus UBMS 90-1 (tetM)Subcutaneous 0.30 1.7 S. aureus UBMS 90-2 (tetM)Oral 1.6 1.8 Subcutaneous 0.53 1.8 S. aureus Smith (sens) Oral 0.81 0.53 Subcutaneous 0.34 0.32 " Single Dose + Median effective dose protecting 50% of the infected mice Testing Results As seen from the above testing, the compounds according to the present invention display good activi-ty against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, -- -especially strains of E. coli, S. aureus and E._.
faecalis containing the tetM or tetK resistant determi-nants. As illustrated in Table I, 9-amino-7-(dimethyl-amino)-6-demethyl-6-deoxytetracycline hydrochloride (A) shows good in vitro activity against tetracycline- re-sistant strains carrying the tetM resistance determi-nant such as S. aureus UBMS 88-5, S-aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and 90-4; and is equally as effective as 7-(dimethylamino)-6-demethyl-6-deoxy-.. ~ .~ 20~~'~Q~

tetracycline hydrochloride (:B) vs. susceptible strains.
7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydro-chloride (B) and 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (A) are assayed in vitro for their ability to inhibit protein synthesis, taking place on either wild 'type or tetM protected ri-' bosomes, using a coupled transcription and translation system. Similarly, 9-amino-7-(diethylamino)-6-de-to methyl-6-deoxytetracycline sulfate (C) shows enhancement of antibacterial activity versus 7-(di-ethylamino)-6-demethyl-6-deoxytetracycline sulfate (D).
Both compounds (A & B) are found to effec-tively inhibit protein synthesis on wild type ribo-somes, having equivalent levels of activity (Table II).
7-(dimethylamino)-6-demethyl-6-deoxytetracycline hydro-chloride (B) is unable to inhibit protein synthesis occurring on tetM protected ribosomes. In contrast, 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetra-2o cYcline hydrochloride (A) is effective in inhibiting protein synthesis occurring on tetM protected ribo-somes, although higher drug levels are required to achieve similar levels of inhibition relative to wild type ribosomes.
The enhanced activity of 9-amino-7-(di-methylamino)-6-demethyl-6-deoxytetracycline sulfate (A) against tetracycline susceptible and resistant organ-isms (tetM) is demonstrated in Table 3 for animals in-fected with representative bacteria. Lowered ED50's are obtained with 9-amino-7-(dimethylamino)-6-de-methyl-6-deoxytetracycline sulfate (A) than with 7-(di-methylamino)-6-demethyl-6-deoxytetracycline hydrochlo-ride (B) in mice with of S. aureus and E. coli which carry the tetM resistance determinant. Similar ED50's are obtained with 9-amino-7-(dimethylamino)-6-demethyl-6-deoxytetracycline sulfate (A) and 7-(di-methylamino)-6-demethyl-6-deoxytetracycline hydrochloride (B) against infections with minocycline susceptible organisms.
As can be seen from Tables 1 and 3, the new 9-amino-7-(substituted amino)~-6-demethyl-6-deoxytetra-cyclines may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinsry tract infections, skin infections, ear infections, wound infections and the like.
The improved efficacy of the new 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines is evidenced by the in vitro activity against- isogenic strains into which the resistant determinants, such as tetM, were cloned (Table 1); the inhibition of protein synthesis by tetM resistant ribosomes (Table 2); and the in vivo activity against experimental infections caused by strains resistant to the tetracyclines, due to the presence of resistant determinants, tetM (Table 3).
When the compounds are employed as antibac-terials, they can be combined with one or more pharma-ceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible pow-ders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups con-taining, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions ccntain-30.
ing from about 0.05 to 5% suspending agent in an iso-tonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to four times per day via any typical route of administration including but not limited to oral, parenteral (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound_employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellu-lose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfac-tants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the pre-paration of pharmaceutical compositions may be advan-tageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for exam-ple, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of preparation and adminis-tration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral admin-istration of the compounds is preferred.

These active compounds may also be adminis-tered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for inject-able use include sterile aqueous solutions or disper-sions and sterile powders for the extemporaneous pre-paration of sterile injectable solutions or disper-sions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
It must be stable under the conditions of manufacture and storage and must be preserved against the contami-2o nating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e. g., glycerol, propylene glycol and liquid polyethyl-ene glycol), suitable mixtures thereof, and vegetable oil.
The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.
Example 1 _[.4-S(4a, l2aa) 1-4 7-F~i mdimethvlaMinol 1 a da 5 5a 6 11 . 12a-octah r~dro-3 10 12 12a-tetrahydroxv A n__; t, 1 11-dioxo-2-na hthacenecarboxamide sulfate '1:1 To a stirred ice bath cooled solution of . 0.444 g of [4S-(4a,12aa)]-4,7-bis(dimethylamino)-1,4,-4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, pre-pared by the procedure described in U.S. Patent 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.101 g of sodium nitrate. The mixture is stirred in the cold for 45 minutes followed by the dropwise addi-tion to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.6 g of the desired product as a solid.
MS(FAB): m/z 503(M+H) and 601(M+H2S04+H).
Example 2 f4S-(4a.12aa)1-7-(Diethylamino)-4-(dimethylamino)-1.4.4a.5.5a.6 11 12a-octahydro-3 10 12 12a-tetra-hydroxy-9-nitro-1 11-dioxo-2-naphthacenecarboxamide sulfate (1:2L
To a stirred ice cooled solution of 0.660 g of [4S-(4a,12aa)]-7-(diethylamino)-4-(dimethylamino) 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra hydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochlo-ride, prepared by the procedure described in U.S.
Patent 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.151 g of sodium nitrate. The mixture is stirred in the cold followed by dropwise addition to 500 ml of diethyl ether. The resulting solid is col-lected, washed with diethyl ether and dried to give 0.8 g of the desired product as a solid.
MS(FAB): m/z 531(M+H) and 629(M+H2S04+H).
Example 3 I4S-(4a.12aa)1-9-Amino-4 7-bis(dimethylamino)-1 4.4a.5.5a.6.11.12a-octahydro-3 10 12 12a tetrahydroxy-1 11-dioxo-2-na~hthacenecarboxamide sulfate ~[1:1~
A mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 1.0 g of 10~ palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pres-sure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 100 ml of diethyl ether, the 2(~'~A'~0 -3 fi-solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid.
MS(FAB): m/z 473(M+H).
Example 4 14S-(4a,12aa)1-9-Amino-4 7-bis_jdimethylamino)-1,4,4a,5,5a 6 11 12a-octahydro-3 10 12 12a-tetra hydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride -(1:1) A mixture of 20.0 g of product from Example 1 in 250 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 10.0 g of 20% palladium-on-carbon and 100 ml of 1N ethanolic hydrogen chloride, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 1 L of diethyl ether, the solid collected, washed with diethyl ether and dried to give 16.0 g of the desired product as an oil. The oil is suspended in 20 ml of distilled water, made acidic with 2.8 ml of 32% hydrochloric acid and decolorized with charcoal. The mixture is filtered through diatomaceous earth and made basic (pH 4.0) with concentrated ammonium hydroxide. The solid is collect-ed at 4°C, washed with pH 4 water and dried in vacuo to give 14.2 g of the desired product as a solid.
1H NMR (CD3SOCD3): d 4.19(s,lH,4-H) and 7.29(s,lH,B-H).
MS(FAB): m/z 473(M+H).
Analysis for C23H28 N407 HC1 6.7% H20 Calc'd: C,50.64; H,6.10; N,10.27; C1,6.50 Found: C,50.72; H,6.07; N,10.27; C1,6.62.

Exampl ~e_5 LS-(4a l2aa)1-9-Amino-4 7 bis(dimethylamino) 1 4 4a 5 5a 6 11 12a-octah dro-3 10 12 12a tetrahvdroxy-1 11-dioxo 2 naphthacenecarboxamide p-toluenesulfonate (1'1) The title compound is prepared by the proce-dure of Example 4, using 20 g of product from Example 1, to give 16.0 g of the desired product as the free base. The free base is suspended in 20 ml of distilled water, made acidic with p-toluenesulfonic acid mono-hydrate and decolorized with charcoal. The mixture is filtered through diatomaceous earth and made basic (pH
4.0) with concentrated ammonium hydroxide. The solid is collected at 4°C, washed with pH 4 water and dried in vacuo to give 16.0- g of the desired product.
Example 6 14S-(4a l2aa)1-9-Amino-7-(diethvlamino) 4 dimethylamino)-1 4 4a 5 5a 6 11 12a or-tah~.~ro 3 10 12 12a-tetrahvdroxy-1 11-dioxo-2-naDhthacenecarboxamidP
sulfate (1-2) The title compound is prepared by the proce-dure of Example 3, using 2.1 g of product from Example 2, to give 1.5 g of the desired product as a solid.
1H NMR (CD3SOCD3): 6 4.25(s,lH,4-H) and 7.27(s,lH,B-H).
MS(FAB): m/z 501(M+H) and 599(M+H2S04+H).
Example 7 LS-(4a.12aa)1-4-(Dimethylaminol 7 (ethylmethv7 amino -1,4 4a 5 5a 6 11 12a-octahydro 3 10 12 12a tetrahydroxy-1.11-dioxo-2-naphthacenecarboxa-~id~
hydrochloride (1'1) A solution of 0.460 g of [4S-(4a,12aa))-4-(dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naph-thacenecarboxamide hydrochloride, prepared by the pro-cedure described in U.S. Patent 3,226,436, 0.5 ml of 97% formic acid and 0.75 ml of 40% aqueous formaldehyde is heated at reflux temperature for 2 hours. The ~~~~~~

reaction mixture is cooled, concentrated in vacuo to half volume and poured into diethyl ether. The result-ing solid is collected, washed with diethyl ether and dried to give 0.3 g of the desired product as a solid.
Example 8 L4S-(4a.12aa)1-4-(Dimethylamino)-7-(ethylmethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3 10 12 12a-tetrahydro-9-nitro-1.11-dioxo-2-naphthacenecarboxamide l0 sulfate (1:1) The title compound is prepared by the proce-dure of Example 1, using 0.46 g of product from Example 7 to give 0.5 g of the desired product as a solid.
Example 9 _ f4S-(4a,12aa)1-9-Amino-4-(dimethylamino)-7-(ethyl-methvlamino)-1.4,4a,5a 6 11 12a-octahydro-3 10 12 12a-tetrah~rdrox~r-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1Z
The title compound is prepared by the proce dure of Example 3, using 1.0 g of product from Example 8, to give 0.8 g of the desired product as a solid.
Example 10 f4S-(4a,12aa)1-4-(Dimethylamino)-7-[(1-methylethyl) aminol-1.4,4a.5,5a 6 11 12a-octahydro-3 10 12 12a tetrahvdroxy-9-nitro-1 11-dioxo-2-naphthacene-carboxamide sulfate (1:1) The title compound is prepared by the proce-dure of Example 1, using 0.48 g of [4S-(4a,12aa)]-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,4a,5,5a,-6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Patent 3,226,436, to give 0.5 g of the desired product as a solid.

Example: 11 f4S-(4a,12aa)1-9-Amino-4-(dimethylamino) 7 f(1 methvlethyl)amino)-1 4 4a 5 5a 6 11 12a octah~dro 310.12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (l-1) The title compound is prepared by the proce-dure of Example 3, using 2.1 g of product from Example 10, to give 1.5 g of the desired product as a solid.
Example 12 I4S-(4a,12aa)1-4-(Dimethylamino) 7 (ethylamino) 1,4,4a,5,5a 6 11 12a-octahvdro-3 10 12 12a tetrahydroxy-9-vitro-1 11-dioxo-2 naphthacene carboxamide sulfate (1°1) The title compound is prepared by the proce-dure of Example 1, using 0.96 g of [4S-(4a,12aa)]-4-(dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphth-acenecarboxamide prepared by the procedure described in U.S. Patent No. 3,226,436, to give 0.9 g of the desired product as a solid.
Examgle 13 f4S-(4a,12aa))-9-Amino-4-(dimethylamino~, 7 (ethyl aminol-1.4 4a 5 5a 6 11 12a-octahydro 3 10 12 12a tetrahvdroxy-1 11-dioxo-2-naphthacenecarboxamide sulfate (1:1) The title compound is prepared by the proce-dure of Example 3, using 1.0 g of product from Example 12, to give 0.7 g of the desired product as a solid.
Examples 14-'i5 Substantially following the methods described in detail hereinabove in Examples 3 and 9, the com-pounds of this invention listed below in Examples 14-35 are prepared.

Example 14 [4S-(4a,12aa )]-9-Amino-4-(dimethylamino)-7-(methyl propylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 15 [4S-(4a,12aa )]-9-Amino-4-(dimethylamino)-7-(butyl-methylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 16 [4S-(4a,12aa )]-9-Amino-4-(dimethylamino)-7-[1-methyl-propylamino)methylamino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphtha-cenecarboxamide sulfate.
Example 17 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(2-methyl-propyl)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 18 [4S-(4a,12aa) )]-9-Amino-4-(dimethylamino)-7-(ethylpro-pylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 19 [4S-(4a,12aa))]-9-Amino-4-(dimethylamino)-7-[(1-methyl-ethyl)ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.

Example 20 [4S-(4a,12aa) )]-9-Amino-4-(dimethylamino)-7-(butyl-ethylamino)-1,4,4a,5,5a,6,11,:12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 21 [4S-(4a,12aa))]-9-Amino-4-(dimethylamino)-7-((1-methyl-propyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 22 [4S-(4a,12aa))]-9-Amino-4-(dimethylamino)-7-[(2-methyl-propyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 23 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-(dipropyl amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 24 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methy-ethyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 25 [4S-(4a,12aa) ]-9-Amino-4-(dimethylamino)-7-(butylpro-pylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 26 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-propyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.

Example 27 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(2-methyl-propyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 28 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-ethyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 29 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-ethyl)(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphtha-cenecarboxamide sulfate.
Example 30 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl ethyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphtha-cenecarboxamide sulfate.
Example 31 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-(dibutyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide sulfate.
Example 32 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-propyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a.-tear.ahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.
Example 33 [4S-(4a,12aa)]-9-Amino-9-(dimethylamino)-7-[(2-methyl.-propyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide sulfate.

-43_.
' Example 34 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-propyl)amino]-i,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11--dioxo-2-naphthacenecar-boxamide sulfate.
Example 35 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(1-methyl-propyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro -3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naph-thacenecarboxamide sulfate.
Examples 36-39 Substantially following the methods described in detail hereinabove in Examples 3 and 11, the compounds of this invention listed below in Examples 36-39 are prepared.
Example 36 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-(propyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 37 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-(butyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 38 [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7-[(2-methyl-propyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 39 [4S-(4a,12aa) ]-9-Amino-4-(dimethylamino)-7-[(1,1-di-methylethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3, 10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarbox-amide sulfate.

2a~~~a~
Examples 40-65 Substantially following the methods described in detail hereinabove in Examples 1 and 2, the com-pounds of this invention listed below in Examples 40-65 are prepared.
Example 40 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(methylpropyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate.
Example 41 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(butylmethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate.
Example 42 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methylpropyl-amino)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 43 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(2-methyl-propyl)methylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3.10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 44 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(ethylpropyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarbox-- amide sulfate.
Examble 45 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-ethyl)ethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

20'~9'~fl3 Example 46 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(butylethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Example 47 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-propyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 48 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(2-methyl-propyl)ethylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 49 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(dipropyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Example 50 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-ethyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxamide sulfate Example 51 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(butylpropyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nit.ro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Exa~le 52 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-propyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

X0'79703 Example 53 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(2-methyl-propyl)propylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 54 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-ethyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 55 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-ethyll(1-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 56 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-ethyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octa-hydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 57 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(dibutyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Example 58 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-propyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3r10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 59 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(2-methyl-propyl)butylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.

Example 60 [4S-(4a,12aa)]-4-(Dimethylami;no)-7-[(1-methyl-propyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Examgle 61 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyl-propyl)(2-methylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate.
Example 62 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(propyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Example 63 [4S-(4a,12aa)]-4-(Dimethylamino)-7-(butyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate.
Example 64 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(2-methyl-propyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-9-nitro-l,ll-dioxo-2-naphthacenecar-boxamide sulfate.
Example 65 [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1,1-dimethyl-ethyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecar-boxamide sulfate.

Claims (17)

1. A compound of the formula:

wherein:

R=NR1R2, and when R1=hydrogen, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-propyl , R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or

2-methylpropyl;
and when R1=1-methylethyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl, R2=2-methylpropyl;
R3 is selected from hydrogen, straight or branched (C1--C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furan-yl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quino-linyl or -(CH2)n COOR5 when n=1-4 and R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group;
or (C6-C10)aryl group;
R4 is selected from hydrogen; straight or branched (C1--C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furan-yl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quino-linyl or -(CH2)n COOR6 when n=1-4 and R6 is selected from hydrogen; straight or branched (C1-C3)alkyl; or (C6-C10)aryl; or R3 and R4 taken together are -(CH2)2W-(CH2)~, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal com-plexes.

2. The compound according to Claim 1, where-in:
R=NR1R2, and when R1=hydrogen, R2= ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl, R2=methyl, ethyl, n-propyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=ethyl, R2=ethyl, n-propyl, n-butyl, or 2-methylpropyl;
and when R1=n-propyl, R2=n-propyl, n-butyl or 2-methylpropyl;
and when R1=n-butyl, R2=n-butyl or 2-methylpropyl;
R3 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group: a heterocycle group selected from 2 or 3-furanyl, 2 or

3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or (CH2)n COOR5 when n=1-4 and R5 is selected from hydro-gen; straight or branched (C1-C3)alkyl group: or (C6-C10)aryl group;
R4 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)n COOR6 when n=1-4 and R6 is selected from hydro-gen; straight or branched (C1-C3)alkyl; or (C6-C10)-aryl; or R3 and R4 taken together are -(CH2)2W(CH2)~, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or sub-stituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable or-ganic and inorganic salts and metal complexes.

3. The compound according to Claim 1, where-in:
R=NR1R2, and when R1 hydrogen, R2=ethyl, n-propyl or 1-methylethyl;
and when R1 methyl;
R2=methyl, ethyl or n-propyl;
and when R1=ethyl;
R2=ethyl;
R3 is selected from a straight or branched (C1-C3)alkyl group: (C6-C10)aryl group; (C7-C9)aralkyl group; or -(CH2)n COOR5 when n=1-4 and R5 is selected from hydro-gen: straight or branched (C1-C3)alkyl group; or (C6--C10)aryl group;
R4 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; or -(CH2)n COOR6 when n=1-4 R6 is selected from hydrogen; straight or branched (C1--C3)alkyl; or (C6-C10)aryl; or R3 and R4 taken together are -(CH2)2W(CH2)~, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxy-gen, sulfur or substituted congeners selected from (L
or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal com-plexes.

4. A compound of the formula:

wherein:
R=NR1R2, and when R1=hydrogen, R2=methyl, ethyl, n-propyl, 1--methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl, R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl:
and when R1=n-propyl, R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl, R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl, R2=2-methylpropyl;
R3 is selected from hydrogen, straight or branched (C1--C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furan-yl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quino-linyl or -(CH2)n COOR5 when n=1-4 and R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group;
or (C6-C10)aryl group;
R4 is selected from hydrogen; straight or branched (C1--C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furan-yl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quino-linyl or -(CH2)n COOR6 when n=1-4 and R6 is selected from hydrogen; straight or branched (C1-C3)alkyl; or (C6-C10)aryl; or R3 and R4 taken to-gether are -(CH2)-2W(CH2)~, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal com-plexes.

5. The compound according to Claim 4, where-in R=NR1R2, and when R1=hydrogen, R2=ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, 2-methylpropyl or 1,1-dimethylethyl:
and when R1=methyl, R2=methy1, ethyl, n-propyl, n-butyl, 1-methylpropyl, or 2-methylpropyl:
and when R1=ethyl, R2=ethyl, n-propyl, n-butyl, or 2-methylpropyl:
and when R1=n-propyl, R2=n-propyl, n-butyl, or 2-methylpropyl;
and When R1=n-butyl, R2=n-butyl or 2-methylpropyl:
R3 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group: a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or (CH2)nCOOR5 when n=1-4 and R5 is selected from hydro-gen: straight or branched (C1-C3)alkyl group; or (C6--C10)aryl group;
R4 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group: (C7-C9)aralkyl group; a heterocycle group selected from 2 or 3-furanyl, 2 or 3-thienyl, 2,3 or 4-pyridyl, di(C1-C3)alkyl substituted pyridyl, benzofuranyl, benzothienyl, quinolinyl or -(CH2)nCOOR6 when n=1-4 and R6 is selected from hydro-gen: straight or branched (C1-C3)alkyl; or (C6-C10) aryl: or R3 and R4 taken together are -(CH2)2W(CH2)2' wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organ-ic and inorganic salts and metal complexes.
(C1-C3)alkyl; (C6-C10)aryl: or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxy-gen, sulfur or substituted congeners selected from (L or D) proline, ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal com-plexes.

6. The compound according to Claim 4, where-in:
R=NR1R2, and when R1=hydrogen, R2=ethyl, n-propyl or 1-methylethyl;
and when R1=methyl, R2=methyl, ethyl or n-propyl;
and when R1=ethyl, R2=ethyl;
R3 is selected from a straight or branched (C1-C3)alkyl group; (C6-C10)aryl group; (C7-C9)aralkyl group: or -(CH2)n COOR5 when n=1-4 and R5 is selected from hydro-gen; straight or branched (C1-C3)alkyl group; or (C6--C10)aryl group;
R4 is selected from straight or branched (C1-C3)alkyl group; (C6-C10)aryl group: (C7-C9)aralkyl group; or -(CH2)n COOR6 when n=1-4 and R6 is selected from hydrogen: straight or branched (C1--C3)alkyl; or (C6-C10)aryl; or R3 and R4 taken together are -(CH2)2W(CH2)2, wherein W is selected from (CH2)n and n=0-1, -NH, -N(C1-C3)alkyl, -N(C1-C4)alkoxy, oxy-gen, sulfur or substituted congeners selected from (L
or D) proline or ethyl (L or D) prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts and metal com-plexes.

7. The compound according to Claim 1, [4S-(4.alpha.,12a.alpha.)]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S-(4a,12a.alpha.)]-9-Amino-4,7-bis(dimethyl-amino)-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tet-rahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydro-chloride (1:1): [4S-(4.alpha.,12a.alpha.)]-9-Amino-4,7-bis(dimeth-ylamino)-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide p-toluenesulfonate (1:1): [4S-(4a,12aa)]-9-Amino-7-(di-ethylamina)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-oct-ahydro-3,10,12 12x-tetrahydroxy-1,11-dioxo-2-naphtha-cenecarboxamide sulfate (1:2): [4S-(4a,12aa)]-9-Amino--4-(dimethylamino)-7-(ethyl-methylamino)-1,4,4a,5a,6,1-1,12x-octahydro-3,10,12,12x-tetrahydroxy-1,11-dioxo-2--naphthacenecarboxamide sulfate (1:1); [4S-(4a,12aa)]-9--Amino-4-(dimethylamino)-7-[(1-methylethyl)amino]-1,4,-4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tetrahydroxy-1,-11-dioxo-2-naphthacenecarboxamide sulfate (1:1): [4S--(4a,12aa)]-9-Amino-4-(dimethylamino)-7-(ethyl-amino)--1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tetrahydrox-y-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)t [4S-(4a,12aa)]-9-Amino-4,7-bis(dimethylamino)-1,4,4a,5,-5a,6,11,12x-octahydro-3,10,12,12x-tetrahydroxy-1,11-di-oxo-2-naphthacenecarboxamide: [4S-(4a,12aa)]-9-Amino-7--(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12 12x-tetrahydroxy-1,11-dioxo-2-naph-thacenecarboxamide; [4S-(4a,12aa)J-9-Amino-4-(dimethyl-amino)-7-(ethyl-methylamino)-1,4,4a,5a,6,11,12a-octahy-dro-3,10,12,12x-tetrahydroxy-1,11-dioxo-2-naphthacenec-arboxamide; [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7--[(1-methylethyl)aminoJ-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecar-boxamide: [4S-(4a,12aa)]-9-Amino-4-(dimethylamino)-7--(ethyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,-12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.

8. The compound according to Claim 4, [4S-(4a,12aa)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6, 11,12x-octahydro-3,10,12,12x-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1); [4S--(4a,12aa)]-7-(Diethylamino)-4-(dimethylamino)-1,4,4a,-5,5a,6,11,12x-octahydro-3,10,12,12x-tetrahydroxy-9-ni-tro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2);
[4S-(4a,12aa)]-4-(Dimethylamino)-7-(ethylmethylamino)--1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tetrahydro--

9-vitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1):[4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methyleth-yl)-amino]-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxami-de sulfate (1:1); [4S-(4a,12aa)]-4-(Dimethylamino)-7--(ethylamino)-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,1-2a-tetrahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarbox-amide sulfate (1:1); [4S-(4a,12aa)]-4,7-Bis(dimethyl-amino)-1,4,4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tetr-ahydroxy-9-vitro-1,11-dioxo-2-naphthacenecarboxamide;
[4S-(4a,12aa)]-7-(Diethylamino)-4-(dimethylamino)-1,4,-4a,5,5a,6,11,12x-octahydro-3,10,12,12x-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide; [4S-(4a,-l2aa)]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,-5a,6,11,12x-octahydro-3,10,12,12x-tetrahydro-9-vitro-1-11-dioxo-2-naphthacenecarboxamide; [4S-(4a,12aa)]-4-(Dimethylamino)-7-[(1-methylethyl)-amino]-1,4,4a,5,5a,-6,11,12x-octahydro-3,10,12,12x-tetrahydroxy-9-vitro-1,-11-dioxo-2-naphthacenecarboxamide; [4S-(4a,12aa)]-4--(Dimethylamino)-7-(ethylamino)-1,4,4a,5,5a,6,11,12a-o-ctahydro-3,10,12,12x-tetrahydroxy-9-vitro-1,11-dioxo-2--naphthacenecarboxamide.

9. A method of producing a compound of the formula:

according to C1a-im 4, which comprises reacting a 7-(sub-stituted amino)-6-demethyl-6-deoxytetracycline of the formula:
with a metal nitrate salt or nitric acid in a strong acid at -5°C to +5°C.

10. The method according to Claim 9 wherein said strong acid is selected from sulfuric acid, tri-fluoroacetic acid, methanesulfonic acid or perchloric acid.

11. A method of producing a compound of the formula:
according to Claim 1, which comprises reacting a com-pound of the formula:

according to Claim 4, with a reducing agent.

12. The method according to Claim 11, wherein said reducing agent comprises hydrogen in an acidic 2-methoxyethanol solvent, in the presence of a suitable catalyst; stannous chloride; soluble metal sulfide in alcoholic solvents; and active metal in mineral acid; active metal couples; a supported catalyst and a transfer hydrogenation reagent; a primary or secondary amine in the presence of formaldehyde.

13. A pharmaceutical composition of matter comprising a compound according to any one of Claims 1 to 3 and 7 in association with a pharmaceutically acceptable carrier.

14. A veterinary composition which comprises a pharmacologically effective amount of a compound according to any one of Claims 1 to 3 and 7 and pharmaceutically acceptable carrier.

15. Use of a compound according to any one of Claims 1 to 3 and 7, or a composition according to Claim 13 or 14, for the prevention, treatment or control of a bacterial infection in a warm-blooded animal.

16. Use of a compound according to any one of Claims 1 to 3 and 7, or a composition according to Claim 13 or 14, for the preparation of a medicament for the prevention, treatment or control of a bacterial infection in a warm-blooded animal.

17. A commercial package comprising a compound according to any one of Claims 1 to 3 and 7, or a composition according to Claim 13 or 14, and instructions associated therewith for use of the compound or composition for the prevention, treatment or control of a bacterial infection in a warm-blooded animal.